Synapse - Sergio Giralt

Results (381)

Interleukin-6 (IL-6) blockade with siltuximab peri-autologous hematopoietic stem cell transplantation (AHCT) may reduce symptom burden by altering the cytokine milieu in older patients with multiple myeloma (MM)

Meeting Abstract

Shah, G.; Holder, J.; Cho, S.; Murata, K.; Devlin, S.; Hoover, E.; Chung, D.; Dahi, P.; Lahoud, O.; Scordo, M.; more...
Clinical Lymphoma, Myeloma and Leukemia (2019)

Fulltext@MSK | Save

Successful pharmacokinetic (PK)-directed dosing of Evomela® (propylene glycol free melphalan, PGF-MEL) for Multiple Myeloma (MM) and AL Amyloidosis (AL) patients undergoing autologous hematopoietic stem cell transplant (AHCT)

Meeting Abstract

Shah, G.; Lin, A.; Grumley, A.; Kamrowski, A.; Schofield, R.; Devlin, S.; Bhatt, V.; Proli, A.; Chung, D.; Dahi, P.; more...
Clinical Lymphoma, Myeloma and Leukemia (2019)

Fulltext@MSK | Save

Stem cell mobilization and autograft purity with novel induction regimens in multiple myeloma

Meeting Abstract

Bal, S.; Landau, H.; Shah, G.; Scordo, M.; Dahi, P.; Lahoud, O.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Lesokhin, A.; more...
Clinical Lymphoma, Myeloma and Leukemia (2019)

Fulltext@MSK | Save

Impact of geriatric vulnerability on outcomes of older patients in allogeneic hematopoietic cell transplantation

Meeting Abstract

Lin, R. J.; Elko, T. A.; Devlin, S. M.; Flynn, J.; Jakubowski, A. A.; Shahrokni, A.; Dahi, P.; Perales, M. A.; Sanchez-Escamilla, M.; Tamari, R.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

The SFGM-TC MDS score at day 180 is associated with post-transplant outcomes in patients with myelodysplastic syndrome who underwent CD34+ selected allogeneic stem cell transplant

Meeting Abstract

Alarcon, A.; Hilden, P. D.; Maloy, M.; Ruiz, J. D.; Sanchez-Escamilla, M.; Yañez, L.; Castillo, N.; Tamari, R.; Shaffer, B.; Castro-Malaspina, H.; more...
Bone Marrow Transplantation (2019)

Fulltext@MSK | Save

A phase II clinical trial of leuprolide for enhancement of immune reconstitution after ex vivo CD34+ cell-selected allogeneic HCT with TBI-based conditioning

Meeting Abstract

Cho, C.; Devlin, S. M.; Avecilla, S. T.; Castro-Malaspina, H.; Giralt, S. A.; Jakubowski, A. A.; Maloy, M.; Maslak, P.; O'Reilly, R. J.; Papadopoulos, E. B.; more...
Bone Marrow Transplantation (2019)

Fulltext@MSK | Save

EASIX score predicts high-grade acute GVHD, non-relapse mortality, and overall survival in adult patients undergoing unmodified or CD34-selected allogeneic HCT

Meeting Abstract

Sanchez-Escamilla, M.; Hilden, P.; Malloy, M.; Ruiz, J. D.; Fatmi, S.; Sauter, C. S.; Ponce, D.; Giralt, S. A.; Scordo, M.; Perales, M. A.
Bone Marrow Transplantation (2019)

Fulltext@MSK | Save

Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/refractory B cell non-Hodgkin lymphoma

Journal Article

Jain, T.; Sauter, C. S.; Shah, G. L.; Maloy, M. A.; Chan, J.; Scordo, M.; Avecilla, S. T.; Batlevi, Y.; Dahi, P. B.; Batlevi, C. W.; more...
Leukemia (2019)

Fulltext@MSK | Save

Standard antithymocyte globulin dosing results in poorer outcomes in overexposed patients after ex vivo CD34(+) selected allogeneic hematopoietic cell transplantation